

UNITED STATES PATENT AND TRADEMARK OFFICE
Trademark Trial and Appeal Board
P.O. Box 1451
Alexandria, VA 22313-1451

kk

Mailed: July 26, 2012

Opposition No. 91204337

Endo Pharmaceuticals Inc.

v.

Endocyte, Inc.

Cheryl S. Goodman, Interlocutory Attorney:

On July 12, 2012, opposer filed an amended notice of opposition. As permitted by Fed. R. Civ. P. 15(a) and Trademark Rule 2.107, opposer's amended notice of opposition is accepted and is now the operative pleading in this case.

Applicant's answer to the amended notice of opposition filed July 18, 2012 is noted as accepted for the record.

Dates are reset as follows:

Deadline for Discovery Conference	8/24/2012
Discovery Opens	8/24/2012
Initial Disclosures Due	9/23/2012
Expert Disclosures Due	1/21/2013
Discovery Closes	2/20/2013
Plaintiff's Pretrial Disclosures	4/6/2013
Plaintiff's 30-day Trial Period Ends	5/21/2013
Defendant's Pretrial Disclosures	6/5/2013
Defendant's 30-day Trial Period Ends	7/20/2013
Plaintiff's Rebuttal Disclosures	8/4/2013
Plaintiff's 15-day Rebuttal Period Ends	9/3/2013

In each instance, a copy of the transcript of testimony, together with copies of documentary exhibits, must be served on the adverse party within thirty days after completion of the taking of testimony. Trademark Rule 2.125.

Briefs shall be filed in accordance with Trademark Rules 2.128(a) and (b). An oral hearing will be set only upon request filed as provided by Trademark Rule 2.129.